Restoration of microbiota balance using spore-forming probiotic microorganisms: a review
Open Access
- 9 June 2026
- journal article
- review article
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (5) , 311-316
Abstract
Intestinal dysbiosis is a common condition associated with a wide range of diseases. Choosing the optimal probiotic therapy remains challenging due to the variety of available strains. Spore-forming probiotics, particularly Bacillus clausii, exhibit high resistance to aggressive gastrointestinal factors and can rapidly restore the gut microbiota. Aim – to summarize current data on the mechanisms of action and clinical efficacy of B. clausii in correcting dysbiotic disorders. A review of recent literature was performed, including systematic reviews, randomized controlled trials, real-world studies (PEGASO), and preclinical studies focusing on B. clausii. B. clausii exerts antagonistic, immunomodulatory, and metabolic effects, and restores intestinal barrier function. According to a systematic review (C. Acosta-Rodríguez-Bueno et al., 2022), a 7-day course of B. clausii significantly reduces the duration of acute diarrhea by 1–2 days and decreases the risk of antibiotic-associated diarrhea by 47–60%. In a prospective study (H. Dang et al., 2024) in children with persistent diarrhea, symptom resolution was achieved in 87.5% of patients by day 7, along with a decrease in fecal calprotectin and an increase in secretory IgA levels. In real-world practice (PEGASO study, С. Giua et al., 2024), 89% of patients rated the efficacy as “good” or “excellent,” adherence to the 7-day course was 94%, and the incidence of adverse events was 2.1%. An experimental study (M. Salem et al., 2025) revealed suppression of the TXNIP/NLRP3 inflammasome cascade and restoration of the gut microbiota following B. clausii treatment in a colitis model. B. clausii is a universal means of primary correction of dysbiosis, capable of restoring the gut microbiota and resolving diarrhea within 7 days. Owing to its transient persistence, after the course the residual disturbances can be objectively assessed, allowing for personalized therapy with other probiotics (lactobacilli, bifidobacteria, Saccharomyces boulardii, etc.) depending on the remaining alterations of the gut microbiota.Keywords
This publication has 46 references indexed in Scilit:
- Safety Assessment and Efficacy of Probiotic Bacillus clausii PBC429™ (MTCC 25459) for Management of DiarrheaProbiotics and Antimicrobial Proteins, 2025
- A Prospective Real-World Study of Bacillus clausii Evaluating Use, Treatment Habits and Patient Satisfaction in Italian Community Pharmacies: The PEGASO StudyDrugs - Real World Outcomes, 2023
- Bacillus clausii for Gastrointestinal Disorders: A Narrative Literature ReviewAdvances in Therapy, 2022
- Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysiseClinicalMedicine, 2020
- Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease SpecificityDigestive Diseases and Sciences, 2020
- Bacillus strains as human probiotics: characterization, safety, microbiome, and probiotic carrierFood Science and Biotechnology, 2019
- The Impact of Dietary Fiber on Gut Microbiota in Host Health and DiseaseCell Host & Microbe, 2018
- Bifidobacteria and the infant gut: an example of co-evolution and natural selectionCellular and Molecular Life Sciences, 2017
- Probiotics, prebiotics and synbiotics- a reviewJournal of Food Science and Technology, 2015
- Bacillus probioticsFood Microbiology, 2011